Treatment with teclistamab, administered subcutaneously at a dose of 1500 µg/kg once weekly, led to a high response rate and an encouraging safety profile in patients with relapsed/refractory multiple myeloma.
Recent Content
- Adding relacorilant to chemo shown to boost survival in ovarian cancer trial
- (no title)
- Trial of myeloma therapy KLN-1010 gets FDA green light to expand to US
- Real-world analysis of multiple myeloma treatments in England using the Cancer Analysis System registry
- (no title)
- Sofi-cel gets FDA breakthrough status for aggressive blood cancers
- (no title)
- Atebimetinib nearly doubles 1-year survival in pancreatic cancer study
- Diagnosis, risk stratification and management of smouldering multiple myeloma
- The addition of CD38 monoclonal antibody to triplet regimens improves survival in newly diagnosed multiple myeloma with high-risk cytogenetics: a systematic review and meta-analysis of randomized controlled trials